CD38 and plasma cell myeloma: Dual-targeting platforms, simultaneously recognizing plasma cell antigens (e.g., CD38, BCMA) and microenvironmental markers (e.g., CXCR4 or PDGFR-β), have shown over 90% internalization in myeloma cells and enhanced stromal penetration in preclinical models [73,100].